Poster Presenter

New Multimodal Iron Oxide Nanoparticles as Nanotools for Cancer Therapy and Biomedical Imaging
Farah Benyettou Yoann Lalatonne, Odile Sainte-Catherine, Mélanie Di Benedetto, Laurence Motte
France

Thanks to their magnetic properties, iron oxide nanoparticles are used as contrast agents for MRI (Endorem®, Resovist®) Secondly, by specific surface coating, nanoparticles can be used as a drug delivery vehicle. On an other hand, Bisphosphonates (BPs) have proven to be powerful adjuvants in the treatment of bone diseases (osteoporosis, Paget's disease…) by inhibiting osteoclast activity (Zometa®, Fosamax®…). Recent studies have shown that in addition to inhibit bone resorption BPs present anti-tumour properties in variety of cancer. However, these properties can not be exploited due to their very high affinity to bone. In order to overcome this problem, one strategy is the vectorization trough iron oxide nanocrystals. The BPs anchoring to the nanoparticle allowed to change the therapeutic target. Within such context, we have elaborated new multifunctional magnetic nanovectors to vectorize therapeutic molecules for therapy and diagnostic applications. BPs are magnetically pilot to reach the tumour instead of been accumulated in bone. Anti-cancer properties of these nanohybrids have been tested in-vitro on different cancer cell lines and in-vivo on nude mice with breast cancer tumour. The therapeutic behaviour is attributed to the BPs internalization by endocytosis uptake through the nanoparticle surface. In presence of the coated particles and magnetic field, we observed a significant slowdown of the tumours growth. Furthermore, the γ-Fe2O3-Alendronate present on the surface free primary amino functions, which can be used for coupling cancer targeting molecules (peptides, folic acid) or dyes. Thus, we have conjugated these functions to folic acid and Rhodamine B under microwave energy. These magneto-fluorescent particles allowed us to image specifically the cell line MDA-MB231 by fluorescence microscopy. As a conclusion, we designed a new therapeutic nanoplatform which could simultaneously imaged in situ (MRI (T2 contrast agent) and fluorescence imaging) and addressed therapeutic molecules by magnetic targeting (magnet) or specific molecules (peptides, antibodies …) for cancer therapy. Thus, this new nanotool makes possible to follow and treat the evolution of cancer diseases.